Biotech success in Australia without the long wait and the big budgets

Last week we at NDF Research told you about the The Coming Boom in Life Sciences in Australia. A great example of the potential upside is a virtually unknown listed biotech company called Dimerix (ASX: DXB). I like this company because of what they can potentially achieve without the long wait or the big budgets traditionally associated with biotechnology. Dimerix is now in Phase II - the mid-stage of clinical trials - with DMX-200. This product is a combination of two existing and approved drugs, irbesartan and propagermanium. Following recent guidance for the FDA, Dimerix now plans to take DMX-200 into Phase III in a rare kidney disorder called FSGS. Using existing drugs and going after a rare disease for the first approval were both smart moves that markedly cut the potential cost and time required to get to market, and there's still a US$10bn market waiting for the larger market indications in kidney disease that will follow. Dimerix shows how we're getting really good at building biotech companies here in Australia. Check out my Dimerix report at (VIEW LINK)